



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/529,721	03/30/2005	Toshiaki Takeda	506.44955X00	8995
20457	7590	11/30/2006	EXAMINER	
ANTONELLI, TERRY, STOUT & KRAUS, LLP			KWON, BRIAN YONG S	
1300 NORTH SEVENTEENTH STREET				
SUITE 1800			ART UNIT	PAPER NUMBER
ARLINGTON, VA 22209-3873			1614	

DATE MAILED: 11/30/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/529,721	TAKEDA ET AL.
	Examiner Brian S. Kwon	Art Unit 1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 30 March 2005.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-9 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-9 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 30 March 2005 is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date: _____
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date <u>2/14/06</u> .	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

Information Disclosure Statement

1. Acknowledgement is made of applicant's submitting of the information disclosure statement (IDS) on February 14, 2006. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement (IDS) has been considered by the examiner.

Priority

2. An application in which the benefits of an earlier application are desired must contain a specific reference to the prior application(s) in the first sentence of the specification of in an application data sheet (37 CFR 1.78(a)(2) and (a)(5)).

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claims 1-9 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the term "treating decubitus", does not reasonably provide enablement for the term "preventing" or "preventive". The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

The factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described in *In re Wands*, 8 USPQ2d 1400 (Fed. Cir. 1988). Among these factors are: (1) the nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. When the above factors are weighed, it is the examiner's position that one skilled in the art could not practice the invention without undue experimentation.

The American Heritage Dictionary (Second College Edition, 1982) defines the term d "prevent" as "anticipate or counter in advance, to keep from happening". The interpretation of the instant claims allows for the complete cure and eradication or total elimination of decubitus by the administration of said compounds.

There are no known compounds of similar structure which have been demonstrated to prevent or cure decubitus. Since this assertion is contrary to what is known in medicine, proof must be provided that this revolutionary assertion has merits. The existence of such a "magic bullet" is contrary to our present understanding of pharmacology. One skilled in the art can reasonably establish the basis and the type of subject to which the instant compounds can be administered in order to have the "prevention" or completely cure or eradication effect.

The relative skill of those in the art of pharmaceuticals and the unpredictability of the pharmacy art is high. The specification does not provide any competent evidence or disclosed tests that are highly predictive for the preventive utility of the instant compounds.

The specification provides the effects of reducing in necrosis or wound of epidermis in rabbit model study (Examples 1-2). However, there is no demonstrated correlation that the tests and results apply to the claimed preventive utility embraced by the instant claims.

Since the efficacy of the claimed composition in preventing decubitus mentioned above cannot be predicted from a priori but must be determined from the case to case by painstaking experimental study and when the above factors are weighed together, one of ordinary skill in the art would be burdened with undue "painstaking experimentation study" to use the invention commensurate in scope with the claims.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 4-6 provide for the use of the N-acylated derivatives of hydroxyproline or a salt thereof, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

For the examination purpose, the claims 4-6 are interpreted as "a method of preventing or treating decubitus...".

Claim Rejections - 35 USC § 101

5. Claims 4-6 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a

process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claims 1-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Kobayashi et al. (EP 1 304 323 A1).

Claims read on a composition comprising an N-acylated derivative of hydroxyproline or a salt thereof (claims 1-3) and method of using said composition for the prevention or treatment of decubitus (claims 4-9). Further limitations include "the N-acylated derivative of hydroxyproline or a salt thereof is contained in an amount of 0.1 to 15% by weight to the total weight" (claims 2, 5 and 8); "an acyl group of the N-acylated derivative of hydroxyproline is the acyl group having 1 to 24 carbon atoms" (claims 3, 6 and 9).

Kobayashi et al. discloses a composition comprising N-acyl derivative of hydroxyproline (i.e., cis-4-hydroxy-L-proline, cis-4-hydroxy-D-proline, cis-3-hydroxy-L-proline, cis-3-hydroxy-D-proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, trans-3-hydroxy-L-proline and trans-3-hydroxy-D-proline) that is useful for improving skin barrier function or improving atopic dermatitis, wherein said N-acyl derivative of hydroxyproline is contained in an amount of 0.01 to 20% by weight based on the total weight (see para. [0009], [0016]-[0027]).

With respect to the claims 1-3,

Although Kobayashi is silent about the functional characteristic or property of said composition in “a preventive or therapeutic agent for decubitis”, such characteristic or property deems to be inherent to the referenced composition, i.e., it was always there. Claims to a composition possessing a particular property or characteristics are still properly rejected by a reference to the same composition, even if the referenced does not address or acknowledge the property.

With respect to the claims 4-9,

The interpretation of the instant claims allow for the inclusion of prophylactic or preventive utility of said composition.

The prior art directing administration of the same composition or compound, in overlapping dosage amounts, inherently possessing same protective utility effect anticipates claims directed to such protective uses encompassed by the instant invention.. Applicant’s attention is directed to Ex parte Novitski 126 USPQ 1389 (BOPA 1993) illustrating anticipation resulting from inherent use, absent a haec verba recitation for such prophylactic utility. In the instant case, as in Ex parte Novitski, the claims are directed to preventing a malady or disease with old and well known compounds of compositions.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or

improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claims 1-9 are rejected under the judicially created doctrine of double patenting over claims 1-8 and 15-19 of USP 7138386.

Although the conflicting claims are not identical, they are not patentably distinct from each other.

With respect to the obviousness over the referenced claims 1-6,

Both of the instant application and the patent are directed to the same composition comprising N-acylated hydroxyproline derivative.

Although the patent is silent about the functional characteristic of said N-acylated hydroxproline as "a preventive or therapeutic agent for decubitus", such property or characteristic deems to be inherent to the referenced composition, i.e., it was always there. Claims to a composition possessing a particular property or characteristics are still properly rejected by a reference to the same composition, even if the referenced does not address or acknowledge the property. Thus, the USP'386 makes obvious the instant invention.

With respect to the obviousness over the referenced claims 7-8 and 15-19,

The prior art directing administration of the same composition or compound, in overlapping dosage amounts, inherently possessing same protective utility effect anticipates claims directed to such protective uses encompassed by the instant invention. Thus, the USP'386 makes obvious the instant invention.

Since the interpretation of the instant claims reciting "comprising" allows for the inclusion of any other unspecified ingredients even in major amounts in said composition, the USP'386 makes obvious the instant invention.

With respect to the determination of dosage amounts of said n-acylated derivative in said composition, those of ordinary skill in the art would have been readily optimized effective dosages as determined by good medical practice and the clinical condition of the individual patient. Determination of the appropriate dosage for treatment involving each of the above mentioned formulations is routinely made by those of ordinary skill in the art and is within the ability of tasks routinely performed by them without undue experimentation, especially in light of the dosage information provided in the prior art.

8. Claims 4-9 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 15-20 of copending Application No. 10/250372. Although the conflicting claims are not identical, they are not patentably distinct from each other because the prior art directing administration of the same composition or compound, in overlapping dosage amounts, inherently possessing same protective utility effect anticipates claims directed to such protective uses encompassed by the instant invention.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

9. In looking in continuity data, it is noted that applicant has numerous issued patent and pending applications encompassing the same or similar subject matter of the instant application. Applicant should review all subject matter considered the same or similar, and submit the appropriate Terminal Disclaimer(s). For example, the copending 10/532721, USP 6692754 and USP 6497889 have same or similar subject matter(s).

Conclusion

10. No Claim is allowed.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Kwon whose telephone number is (571) 272-0581. The examiner can normally be reached Tuesday through Friday from 9:00 am to 7:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached on (571) 272-0718. The fax number for this Group is (571) 273-8300.

Any inquiry of a general nature of relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications may be obtained from Private PAIR only. For more information about PAIR system,

see <http://pair-direct.uspto.gov> Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Brian Kwon
Primary Patent Examiner
AU 1614

A handwritten signature in black ink, appearing to read "B. Kwon".